Matrixyl

KTTKS is a subfragment of the C-terminal propeptide of type I procollagen. When collagen is broken down, fragments like this appear in the matrix, and fibroblasts read them as a repair signal — this is the matrikine concept. Attaching a palmitoyl chain makes the otherwise very hydrophilic pentapeptide lipophilic enough to partition into the stratum corneum, which is what made it usable in cosmetics at all. In fibroblast culture pal-KTTKS increases collagen I, collagen III and fibronectin synthesis at nanomolar to low micromolar concentrations. There is no receptor cleanly identified for it; the signalling is described phenomenologically rather than mechanistically.

Targets: Dermal fibroblasts, Collagen I and III synthesis, Fibronectin, Glycosaminoglycans

• · The pivotal trial used just 3 ppm (0.0003%) of pal-KTTKS. Commercial products list 3-8% of the trade solution, which is typically a 100-500 ppm peptide concentration. More is not better here — the dose-response is flat and very low concentrations worked.

Work out your exact syringe units →

• rareIrritation— One of the best-tolerated cosmetic peptides; most complaints trace to the vehicle.

• synergyghk-cu-topical — Independent routes to increased collagen output; a very common layering pair.
• redundantmatrixyl-3000 — Overlapping matrikine signalling — pick one rather than stacking both at full strength.
• synergytretinoin — Retinoid-driven collagen synthesis plus matrikine signalling; the combination is widely used and well tolerated.

• · Standardised photography at 0, 6 and 12 weeks.

Cosmetic ingredient (INCI Palmitoyl Pentapeptide-4) approved worldwide.

• Robinson et al. 2005, topical palmitoyl pentapeptide improves photoaged facial skin (Int J Cosmet Sci) (trial)
• Katayama et al. 1993, pentapeptide from type I procollagen promotes extracellular matrix production (preclinical)

This is the matrikine concept in its cleanest form, and it is worth understanding properly because it explains the peculiar dose-response. When type I collagen is degraded, the propeptide regions are released as fragments. Katayama's group identified KTTKS as the minimal sequence within the C-terminal propeptide of procollagen I that stimulates matrix production, and showed it works across multiple mesenchymal cell types. The biological logic is a feedback loop: fragments of broken collagen tell fibroblasts that collagen has been broken, and fibroblasts respond by making more. That is a damage-sensing signal, not a growth factor signal, and damage-sensing signals are typically saturable at very low concentrations because their job is detection, not amplitude encoding. This is exactly why the pivotal Robinson trial worked at 3 parts per million. Three ppm is 0.0003%. It is an almost absurdly low concentration for a cosmetic active, and it worked in a 93-subject randomised vehicle-controlled study. It also means the dose-response above that is flat, and every product selling '8% Matrixyl' is selling you carrier solution. In fibroblast culture, pal-KTTKS increases collagen I, collagen III, fibronectin and glycosaminoglycan production at nanomolar to low micromolar concentrations. The uncomfortable gap in the story is that no receptor has ever been identified. There is no cloned KTTKS receptor, no characterised signalling cascade, no described second messenger. The effect is described phenomenologically — apply peptide, measure procollagen output — and the intermediate steps are a black box. That is a real weakness and the field has not closed it in thirty years.

The most common error is chasing concentration. Products advertise 3%, 5% or 8% Matrixyl, which refers to the trade solution, and buyers assume more is better. The pivotal trial used 3 ppm — 0.0003% — and the dose-response above that is flat because this is a saturable detection signal, not a dose-proportional agonist. You are almost certainly already past the ceiling in any product that contains it at all. The second problem is the solubility trap for DIY formulators: the palmitoyl chain means it will not dissolve in plain water, and people who dump powder into water get an undissolved slurry that does nothing. Wet it with pentylene glycol, propylene glycol or a splash of ethanol first, then dilute out. Third, expectation: the Robinson effect size was statistically significant and cosmetically small. It is a real result, not a dramatic one. Anyone showing you a dramatic before-and-after from pal-KTTKS alone is showing you lighting.

• Unidentified fibroblast matrikine receptor — No receptor cloned, no Kd published. Active in fibroblast culture at nanomolar to low micromolar concentrations.

  Increased transcription of collagen I, collagen III, fibronectin and glycosaminoglycans. The mechanism between binding and transcription is genuinely unknown.

• Collagen I and III synthesis — Downstream output, not a binding target

  The measured endpoint in essentially all of the preclinical work.

• Fibronectin — Downstream output

  Fibronectin is the scaffold new collagen assembles on, so raising it matters more than the collagen numbers alone suggest.

• Robinson et al. randomised vehicle-controlled facial trial of topical palmitoyl pentapeptide (Int J Cosmet Sci) Double-blind randomised vehicle-controlled · n=93 · 12 weeks · 2005

  93 Caucasian women aged 35-55, moisturiser with versus without pal-KTTKS at 3 ppm for 12 weeks. Significant improvement versus vehicle control in wrinkle and fine-line reduction by both instrumental measurement and expert grading, and well tolerated. This is the only proper double-blind vehicle-controlled facial trial in the entire cosmetic peptide category.

Week 0-4: nothing measurable. This is normal and is not a reason to abandon it. Week 6-8: the earliest point instrumental measures pick up change. Week 12: the endpoint at which Robinson separated from vehicle on wrinkle length and depth. Week 12-24: continued slow gain, then plateau. Discontinuation: the effect is structural rather than hydration-based, so it decays over months rather than days, but it does decay.

This is the most stack-friendly peptide in the category. It is not oxidised by air, not destroyed by acids, not reduced by vitamin C, not degraded by retinoids, and has no metal chemistry to disturb. Matrixyl plus GHK-Cu is the classic pairing and a genuinely defensible one, because they drive collagen output through entirely independent routes and there is no chemical conflict as long as you are not also running ascorbic acid in the same layer. Matrixyl plus tretinoin is the combination with the strongest theoretical case in this whole class — retinoid-driven procollagen transcription plus matrikine signalling — and it is well tolerated because pal-KTTKS is essentially non-irritating. Matrixyl plus Matrixyl 3000 is the one to avoid, not because it is dangerous but because you are paying twice for overlapping matrikine signalling that is already saturated at 3 ppm. Layering order barely matters; because it is lipophilic it does fine over a hydrating layer and under an occlusive.

Matrixyl has the best clinical evidence in the cosmetic peptide category and it is still weaker than a mid-strength retinoid. Treat it as the peptide you add to a retinoid routine, not the one you use instead. Against GHK-Cu, Matrixyl has the better trial and GHK-Cu has the better mechanism — GHK-Cu's MMP/TIMP effects address matrix degradation, which Matrixyl does not touch, so they are complementary rather than competing. Against Matrixyl 3000, the plain version has the independent randomised trial and the blend has manufacturer panels; on evidence alone, plain Matrixyl wins, even though 3000 is the more commercially successful product. Against Matrixyl Synthe'6, Synthe'6 has the broader claimed target list including basement membrane components, and no independent human data at all.

$6–$55/month. Raw pal-KTTKS powder is around $30-80 per gram, but because the effective concentration is measured in ppm a single gram is effectively a lifetime supply — DIY cost per month is a few dollars. Finished products run $10-55 a month. Market observation, not a sourced pricing study.

• ?No receptor has ever been identified for KTTKS. Thirty years after Katayama, the signalling between peptide and transcription is unmapped.
• ?Whether the active species in skin is the intact palmitoylated lipopeptide or free KTTKS released by esterase cleavage has never been determined.
• ?No quantified human topical bioavailability figure exists.
• ?The Robinson trial was conducted by Procter and Gamble scientists on a P&G formulation. It is well-designed and vehicle-controlled, which is why it counts, but it is not independent of commercial interest.
• ?The 3 ppm figure is confirmed from the trial, but whether the dose-response is truly flat above it or simply untested at higher concentrations in humans is unknown.
• ?The molecular weight of 802.1 Da in the Core record is for the free acid form; salt forms and vendor assay conventions vary.

• Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL, International Journal of Cosmetic Science, 2005 · PMID 18492182

  The pivotal trial. 93 subjects, 12 weeks, 3 ppm, vehicle-controlled, positive. Nothing else in this class comes close.

• A pentapeptide from type I procollagen promotes extracellular matrix production Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM, Journal of Biological Chemistry, 1993 · PMID 8486721

  The origin of the whole matrikine idea. Identifies KTTKS as residues 212-216 of procollagen alpha-1(I) and the minimal active unit.

• Topically applied KTTKS: a review Abu Samah NH, Heard CM, International Journal of Cosmetic Science, 2011 · PMID 21535443

  An independent review of the delivery and efficacy literature, from a skin permeation group rather than a supplier.

• Microneedle enhanced delivery of cosmeceutically relevant peptides in human skin Mohammed YH, Yamada M, Lin LL, Grice JE, Roberts MS, Raphael AP, Benson HA, Prow TW, PLoS One, 2014 · PMID 25033398

  Directly measures how much microneedling improves delivery of this class of peptide into human skin.

• Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM, Frontiers in Chemistry, 2020 · PMID 33195061

  A good independent survey of the whole cosmetic peptide field, with the matrikines placed in context.